Navigation Links
New therapy is tolerable in lung cancer
Date:5/31/2013

CHICAGO, IL (May 28, 2013)A promising new therapy for the most common form of lung cancer appears to produce largely manageable side effects, and an ongoing clinical trial is determining whether the compound treats tumors more effectively than what's on the market, according research that scientists at Fox Chase Cancer Center will present at the 49th Annual Meeting of the American Society of Clinical Oncology on Saturday, June 1.

"We're very excited about this drug," says Hossein Borghaei, DO, chief of thoracic medical oncology at Fox Chase. "I think if we learn how to use it appropriately, and manage the side effects effectively, it will be a good drug to have in our armamentarium."

Lung cancer is the number one cause of death from cancer. Currently, patients with a metastatic form of the most common form of lung cancernon-small cell lung cancer (NSCLC)are treated with a combination of various chemotherapy drugs. If that fails, they are typically treated with a single agent. "We're trying to find a new option," says Borghaei, also the director of Lung Cancer Risk Assessment at Fox Chase.

The drug, known as nivolumab, is a monoclonal antibody that targets the immune system's response to cancer. Specifically, it acts on the pathway that protects the tumor from the efforts of the immune system to destroy it. Treatment with nivolumab is like taking the brakes off the immune system, says Borghaei"it allows the body's own immune system to recognize the tumor as foreign and attack it." A similar drug, ipilimumab, has been approved for melanoma.

Because nivolumab acts on the immune system, Borghaei explains, he and his colleagues have noted different side effects than what often occur with standard chemotherapy. These side effects, reported on other studies with this drug, include thyroid inflammation or inflammation of the colon.

The drug's seller, Bristol-Myers Squibb, has sponsored other research that suggests nivolumab may have some effect on lung cancerin a previously published phase 1 trial in patients with NSCLC, 33% responded to the treatment.

To test the drug's effects further, Borghaei and his colleagues are conducting two phase III trials of nivolumab, comparing its effectiveness to another commonly used chemotherapy drugdocetaxelin patients with NSCLC of different histologies who have already failed previous treatments.

The trials, which is ongoing, aims to enroll several hundred people worldwide, and will likely be complete in a few years. Fox Chase alone has enrolled approximately 10 people so far, says Borghaei. "We're going to keep going until we're told to stop."

He encourages patients with NSCLC who think they may benefit from trying nivolumab to discuss the option with their doctors. "Every drug patients get now was once experimental," he says. "There are a lot of new drugs for lung cancer being investigated, so a lot of reason to feel hopeful that new therapies are on the horizon. But the only way this will happen is if patients participate in experimental trials."


'/>"/>

Contact: Diana Quattrone
diana.quattrone@fccc.edu
215-815-7828
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Sixth Annual One Day Sale on Gift Certificates Will Take Place on June 19, 2013
2. Gene Therapy May Protect Against Flu Pandemics
3. Talk Therapy Can Ease Depression, But No Single Type Deemed Best
4. Avatar therapy helps silence voices in schizophrenia
5. Radiotherapy remains the treatment of first choice for high-risk low-grade glioma
6. Researchers provide rationale for use of targeted immunotherapy in sarcomatoid lung carcinomas
7. US Infusion Therapy Devices Market Analysis and 2019 Forecasts in New Research Report at RnRMarketResearch.com
8. Dr. Leslie Gerstman Is Now Offering the Non-surgical Facelifting Procedure – Ultherapy – in NYC and NJ
9. Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld
10. Ayurveda Education Programs Offered by the California College of Ayurveda Include Panchakarma Certification, Practitioner Courses, and Body Therapy Classes
11. Icahn School of Medicine at Mount Sinai Grants Exclusive License to Cellular Dynamics International for Development of a Cellular Therapy for Cardiac Muscles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... PawPaws brand pet supplements owned by Whole Health ... the health of felines. The formula is all-natural and is made from Chinese herbs ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia ...
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
Breaking Medicine Technology: